The Equine Rotavirus Vaccine from Pfizer Animal Health now has an updated appearance and packaging to reflect the current manufacturer. Originally produced by Fort Dodge Animal Health, the 2009 acquisition of Wyeth by Pfizer Inc., brought the Equine Rotavirus Vaccine to the Pfizer Animal Health vaccine portfolio.
The Equine Rotavirus Vaccine is conditionally licensed for the vaccination of pregnant mares to provide the passive transfer of antibodies to foals against equine rotavirus.
Equine rotavirus is a major infectious cause of foal diarrhea. The Equine Rotavirus Vaccine is the only conditionally licensed vaccine available to help prevent rotavirus infections in foals and should be administered to pregnant mares in the eighth, ninth, and tenth month of gestation. The vaccination of mares increases the rotavirus antibody titers present in the mare’s milk which are transferred to the foal via colostrum to help reduce the incidence and severity of foal diarrhea due to rotaviral infection. The Equine Rotavirus Vaccine has been used in mares since 1996 with no significant side effects.
"We are very happy to bring the Equine Rotavirus Vaccine under the Pfizer Animal Health brand," said Andrea Wright, DVM, MVSc, marketing manager of equine biologicals for Pfizer Animal Health.
Rotavirus is transmitted orally via direct contact with infected feces and damages the lining of the small intestine once ingested, resulting in diarrhea. Infected foals can shed the virus for up to ten days and should be isolated from other horses. Strict biosecurity measures should be e